Australian Centre for RNA Therapeutics in Cancer
The Australian Centre for RNA Therapeutics in Cancer is developing the next generation of precision cancer treatments using RNA technologies.
Establishing Australia's Centre for RNA Therapeutics in Cancer
In 2023, RNA Foundry in Western Australia received $5 million over 5 years with a further $4 million over 4 years subject to exceptional progress. For a total investment of up to $9 million over 9 years, thanks to funding from the Cancer Research Trust.
The team is on a mission to accelerate the translation of promising research into new treatments for some of the most aggressive and difficult-to-treat cancers.
The team has used CRT funding, and the additional funding it has leveraged, to build the infrastructure, expertise and manufacturing capability required to design, produce and test new RNA-based cancer therapies.
By bringing together experts in cancer biology, RNA technology and clinical translation, the Centre is strengthening Western Australia’s leadership in precision cancer medicine, creating a platform for future cancer breakthroughs.
Targeting Cancers with the Greatest Unmet Need
Patients diagnosed with pancreatic cancer, triple negative breast cancer, and advanced forms of ER+ breast cancer, lung cancer and sarcoma often face limited treatment options and poor outcomes.
These complex cancers can be difficult to treat with conventional therapies, highlighting the need for new approaches that are more effective, targeted and adaptable to individual patients.
RNA therapeutics offer a new approach to cancer treatment by enabling precision medicines to be designed around the biology of individual tumours.
From cancer vaccines to direct tumour-targeting therapies, these technologies have the potential to improve treatment effectiveness while reducing toxicity and improving quality of life for people living with cancer.
Precision Medicine
Developing therapies tailored to the unique genetic characteristics of individual tumours.
Reducing Toxicity
Advancing targeted approaches designed to reduce treatment burden and improve quality of life.
“The CRT first brought single-cell sequencing ability to WA, which was very enabling for a lot of researchers to discover more about specific cancers. Following a similar paradigm, this mRNA technology has been enabling for cancer researchers to do more translational work, applying this discovery knowledge.
The large quantum of funding, and the 5-9 year timescales of support the CRT provides allows us to be truly strategic and coordinated in our approach. This long-term vision is essential to be ambitious and transformative for WA cancer research and people in WA with cancer.”
Professor Archa Fox
Professor and Director of the Australian Centre for RNA Therapeutics in Cancer
Syndicate Investors Matched Funding
- Western Australian Future Health Research and Innovation Fund
- National Research Infrastructure for Australia
- Therapeutic Innovation Australia
- The University of Western Australia
- Cancer Council WA
- The Ian Potter Foundation
- The Kids Research Institute Australia
- Harry Perkins Institute of Medical Research
- Curtin University
- The RNA Society
- Cytiva
- Lexogen